3rd Party Biotechnology Industry News

Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a [...]

Senior Writer Darren Incorvaia talks with industry leaders and experts [...]

Pfizer is paying Innovent $650 million upfront to partner on [...]

The FDA has delayed its approval decision on Beren Therapeutics’ [...]

Hoth Therapeutics’ search for salvation in the stars appears to [...]

GSK is pulling back the curtain on the phase 3 [...]

D&D Pharmatech has linked its GLP-1/glucagon receptor agonist to improvements [...]

Apogee Therapeutics has secured a promise of up to $1.3 [...]

Kardigan may have only launched last year, but it seems [...]

Amid an intensifying debate over how Washington should counter China’s [...]